Project description
Non-viral gene therapy for intervertebral disc degeneration
Intervertebral disc (IVD) degeneration is a main cause of chronic low back pain and osteoarthritis of the joints, affecting many individuals worldwide. To restore tissue health in affected patients, the EU-funded CARTHAGO project is working on a non-viral gene therapy approach based on the delivery of oligonucleotides and encoding nucleic acids. This strategy combined with ultrasound overcomes accessibility issues of cartilaginous tissues encountered by traditional drugs and enhances tissue penetration and transfection. The work will be carried out by early-stage researchers who will also acquire transferable skills for a career in the field.
Fields of science
- natural sciencesbiological sciencesbiochemistrybiomoleculesnucleic acids
- medical and health sciencesmedical biotechnologygenetic engineeringgene therapy
- social scienceseconomics and businessbusiness and managemententrepreneurship
- medical and health sciencesmedical biotechnologynanomedicine
- natural sciencesphysical sciencesacousticsultrasound
Programme(s)
Funding Scheme
MSCA-ITN-ETN - European Training NetworksCoordinator
3584 CX Utrecht
Netherlands
See on map
Participants (11)
751 05 Uppsala
See on map
400012 Cluj-napoca
See on map
8000 Aarhus C
See on map
02150 Espoo
See on map
4200 135 Porto
See on map
7270 Davos Platz
See on map
31-007 Krakow
See on map
2573 HT 'S-gravenhage
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
Participation ended
NG7 1FD Nottingham
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
7522 NB Enschede
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
07745 Jena
See on map